STOCK TITAN

Jasper Therapeutics (JSPR) SEC Filings

JSPR NASDAQ

Jasper Therapeutics filings document a clinical-stage biotechnology issuer developing briquilimab for mast cell driven diseases. Recent Form 8-K reports furnish quarterly and year-end financial results, corporate updates, briquilimab clinical data in chronic spontaneous urticaria and related extension studies, asthma study disclosures, and executive leadership changes.

The filings also identify Nasdaq-listed voting common stock under JSPR and redeemable warrants under JSPRW, and include material-event disclosures involving capital structure, material agreements, shareholder voting matters and corporate reorganization actions tied to the company's operating plan.

Rhea-AI Summary

Jasper Therapeutics, Inc. (JSPR) reported that Armistice Capital, LLC and its managing member, Steven Boyd, each may be deemed to beneficially own 123,102 shares of Voting Common Stock, or 9.99% of the class, as of September 30, 2026. Armistice Capital has shared voting and dispositive power over the shares under its investment management agreement with Armistice Capital Master Fund Ltd., which directly holds them.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.96%
Tags
ownership
-
Rhea-AI Summary

Jasper Therapeutics, Inc. (JSPR) reported $8.0 million of third-quarter revenue from drug supplies and compounds delivered under the Mirador license, with matching $8.0 million costs. Third-quarter net loss was $144.5 million, versus $18.7 million a year earlier, including $129.5 million of acquired in-process research and development expense after the July 16 acquisition of Kira Pharmaceuticals. Jasper raised approximately $132.0 million in gross proceeds through a preferred-stock financing and effected a 1-for-30 reverse stock split on November 6; share data were retrospectively adjusted.

At September 30, Jasper had $135.3 million in cash and cash equivalents; operating cash used in the nine months ended September 30, 2026 was $27.0 million, compared with $55.3 million a year earlier. Jasper concluded substantial doubt exists about its ability to continue as a going concern, citing potential cash-settlement obligations tied to preferred-stock conversion if stockholder approval is not obtained or shares are not delivered on time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.96%
Tags
quarterly report
-
Rhea-AI Summary

Jasper Therapeutics reported third-quarter 2026 results and a clinical-program update. Revenue for the quarter ended September 30, 2026 was $8.0 million, compared with — in the year-earlier quarter. Total operating expenses were $152.173 million, including $129.494 million in acquired in-process research and development expense; net loss was $144.455 million, versus $18.736 million a year earlier. Cash and cash equivalents were $135.349 million at September 30, 2026, compared with $28.692 million at December 31, 2025.

Following its acquisition of Kira Pharmaceuticals, Jasper completed enrollment in the first cohort of its Phase 2 renal basket study of vensobafusp alfa in patients with IgA nephropathy (IgAN), and enrolled the first patient with immune complex membranoproliferative glomerulonephritis (IC-MPGN). The company also began an expansion cohort for focal segmental glomerulosclerosis (FSGS); its first patient is expected to be dosed in Q1 2027. Interim IgAN cohort data are expected in Q4 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.96%
Tags
current report
Rhea-AI Summary

Jasper Therapeutics, Inc. (JSPR) adjourned its special stockholders’ meeting on November 13, 2026, without conducting business because there were not enough voting common shares present or represented to constitute a quorum. The meeting will reconvene virtually on December 1, 2026, at 10:00 a.m. Pacific Time. The September 28, 2026 record date and the proposals to be voted on remain unchanged.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.96%
Tags
current report
-
Rhea-AI Summary

Jasper Therapeutics, Inc. (JSPR) is the issuer in a Schedule 13G reporting that Affinity Asset Advisors, LLC and its managing member, Michael Cho, each beneficially own the same 1,850,000 shares, approximately 5.6% of common stock as of September 30, 2026. The reported shares are held directly by Affinity Healthcare Fund, LP. Jasper had 33,274,561 common shares outstanding as of September 28, 2026, the basis cited for the ownership percentages.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.96%
Tags
ownership
-
Rhea-AI Summary

Jasper Therapeutics, Inc. (JSPR) announced results of its offer to purchase all outstanding warrants to purchase its common stock. The offer expired at 12:00 a.m. Eastern Time on November 7, 2026.

Holders properly tendered and did not withdraw 8,510,658 warrants, approximately 68.94% of outstanding warrants. Jasper expects to pay $2,757,453.19 in cash at $0.324 per warrant, without interest, with payment to be made promptly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.91%
Tags
current report
Rhea-AI Summary

Jasper Therapeutics, Inc. (JSPR) set a 1-for-30 reverse stock split of its voting common stock, effective at 12:01 a.m. Eastern Time on November 6, 2026. The company said outstanding shares will decline from approximately 33.3 million as of October 26, 2026 to approximately 1.11 million after the split, subject to fractional-share treatment. Authorized shares will remain at 490 million.

Fractional shares will be paid in cash based on each fraction multiplied by the November 5, 2026 closing sales price reported on the Nasdaq Capital Market. The split also applies to shares issuable under outstanding warrants and stock options, with proportionate exercise-price adjustments, and proportionately adjusts shares available under equity incentive plans. Jasper identified risks that it may not regain or maintain Nasdaq continued-listing compliance and that the split may reduce share liquidity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.48%
Tags
current report
-
Rhea-AI Summary

Jasper Therapeutics, Inc. (JSPR) is the issuer in a beneficial-ownership report by Bank of America Corporation, which lists 2,133,861 Voting Common Stock shares, or 6.4% of the class. Bank of America reports shared voting and shared dispositive power over 2,133,861 shares, and zero sole voting and sole dispositive power.

The report is made by Bank of America Corporation on behalf of itself and its wholly owned subsidiaries BofA Securities, Inc., Bank of America, N.A., and Merrill Lynch International. The 6.4% calculation uses Jasper's 33,274,561 shares outstanding as of September 28, 2026, as disclosed in its DEFA14A on October 19, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.84%
Tags
ownership
-
Rhea-AI Summary

Jasper Therapeutics, Inc. (JSPR) amended its cash tender offer to purchase up to 12,345,707 outstanding warrants for $0.324 per warrant, without interest. The warrants are exercisable for common stock at $2.92 per share, and Jasper states that no trading market exists for them. The amendment also removes references to Sections 27A and 21E in its forward-looking-statements disclosure.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.90%
Tags
ownership
Rhea-AI Summary

Jasper Therapeutics, Inc. asks stockholders at a virtual special meeting on November 13, 2026 to approve common-stock issuance upon conversion of preferred stock issued for its completed Kira acquisition and $132 million PIPE financing, ratify Patrick Crutcher’s board appointment, and authorize adjournment if needed. The merger closed July 16, 2026, and the PIPE financing closed July 20; the merger itself is not up for approval. Conversion could result in a maximum 604,302,051 common shares—320,289,040 merger-related and 284,013,011 PIPE-related—subject to beneficial-ownership limits. Taken together, the Merger Preferred, PIPE Preferred and Kira Options would represent approximately 95% of issued and outstanding Common Stock as of September 28, 2026 on an as-converted basis.

Conversion is also subject to sufficient authorized shares and conditional Nasdaq approval, and Jasper says issuance would dilute existing holders. The company disclosed it no longer meets Nasdaq’s $1.00 minimum bid-price and $2,500,000 stockholders’ equity requirements; the bid-price compliance period ends November 30, 2026. Stockholders authorized a 1-for-15 to 1-for-35 reverse split, but the board has not effected it or selected a ratio. The board recommends “FOR” all four proposals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
proxy

FAQ

How many Jasper Therapeutics (JSPR) SEC filings are available on StockTitan?

StockTitan tracks 89 SEC filings for Jasper Therapeutics (JSPR), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Jasper Therapeutics (JSPR)?

The most recent SEC filing for Jasper Therapeutics (JSPR) was filed on November 16, 2026.